Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study Agarwal, N., Loriot, Y., McGregor, B., Dreicer, R., Dorff, T. B., Maughan, B., Kelly, W., Pagliaro, L. C., Srinivas, S., Squillante, C., Vaishampayan, U. N., Liu, Y., Curran, D., Choueiri, T. K., Pal, S. K. AMER SOC CLINICAL ONCOLOGY. 2020

View details for Web of Science ID 000529525900208